Given the relatively low frequency of the incidence of parkinsonian symptoms observed with VPA (which are reversible upon cessation of VPA), one may assume that also Emo carries only a minor risk for parkinsonism and that none of the FDA approve compounds will affect SNCA expression to an extent which could increase the risk of PD28. The gene discussed is SNCA; the disease is Parkinsonism.